ABOS icon

Acumen Pharmaceuticals

1.06 USD
-0.01
0.93%
Updated May 20, 3:54 PM EDT
1 day
-0.93%
5 days
0.95%
1 month
0.00%
3 months
-23.19%
6 months
-55.27%
Year to date
-42.70%
1 year
-72.40%
5 years
-94.73%
10 years
-94.73%
 

About: Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers.

Employees: 52

0
Funds holding %
of 7,202 funds
Analysts bullish %

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

22% more first-time investments, than exits

New positions opened: 11 | Existing positions closed: 9

0% more funds holding

Funds holding: 79 [Q4 2024] → 79 (+0) [Q1 2025]

3.81% less ownership

Funds ownership: 70.73% [Q4 2024] → 66.92% (-3.81%) [Q1 2025]

33% less call options, than puts

Call options by funds: $45K | Put options by funds: $67K

39% less capital invested

Capital invested by funds: $73.1M [Q4 2024] → $44.8M (-$28.3M) [Q1 2025]

58% less repeat investments, than reductions

Existing positions increased: 14 | Existing positions reduced: 33

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$4
277%
upside
Avg. target
$7.50
608%
upside
High target
$11
938%
upside

2 analyst ratings

positive
100%
neutral
0%
negative
0%
UBS
Colin Bristow
277%upside
$4
Buy
Maintained
28 Mar 2025
HC Wainwright & Co.
Andrew Fein
938%upside
$11
Buy
Maintained
28 Mar 2025

Financial journalist opinion

Based on 3 articles about ABOS published over the past 30 days

Neutral
Seeking Alpha
1 week ago
Acumen Pharmaceuticals, Inc. (ABOS) Q1 2025 Earnings Call Transcript
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS ) Q1 2025 Earnings Conference Call May 13, 2025 8:00 AM ET Company Participants Alex Braun - Head, Investor Relations Dan O'Connell - Chief Executive Officer Matt Zuga - Chief Financial Officer and CBO Dr. Jim Doherty - President and CDO Dr. Eric Siemers - Chief Medical Officer Conference Call Participants Sarah Medeiros - Cantor Fitzgerald Tom Shrader - BTIG Ting Liu - UBS Operator Good day and thank you for standing by. Welcome to the Acumen Pharmaceuticals Q1 2025 Conference Call and Webcast.
Acumen Pharmaceuticals, Inc. (ABOS) Q1 2025 Earnings Call Transcript
Neutral
GlobeNewsWire
1 week ago
Acumen Pharmaceuticals to Participate in the Bank of America Healthcare Conference
NEWTON, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer's disease, announced today that management will participate in in a fireside chat at the Bank of American Healthcare Conference on Wednesday, May 14, 2025, at 8:15 a.m. PT/11:15 a.m. ET.
Acumen Pharmaceuticals to Participate in the Bank of America Healthcare Conference
Neutral
GlobeNewsWire
1 week ago
Acumen Pharmaceuticals to Report First Quarter 2025 Financial Results on May 13, 2025
NEWTON, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer's disease, today announced that the Company will report first quarter 2025 financial results on Tuesday, May 13, 2025. The Company will host a conference call and live audio webcast at 8:00 a.m. ET to provide a business and financial update.
Acumen Pharmaceuticals to Report First Quarter 2025 Financial Results on May 13, 2025
Neutral
GlobeNewsWire
1 month ago
Acumen Pharmaceuticals Showcases pTau217 Trial Screening Progress in Phase 2 ALTITUDE-AD Trial and Preclinical Research Methods at AD/PD 2025 and AAN Annual Meeting
Biomarker results from Phase 1 INTERCEPT-AD trial of sabirnetug in patients with early Alzheimer's disease recently published in The Journal of Prevention of Alzheimer's Disease Biomarker results from Phase 1 INTERCEPT-AD trial of sabirnetug in patients with early Alzheimer's disease recently published in The Journal of Prevention of Alzheimer's Disease
Acumen Pharmaceuticals Showcases pTau217 Trial Screening Progress in Phase 2 ALTITUDE-AD Trial and Preclinical Research Methods at AD/PD 2025 and AAN Annual Meeting
Neutral
Seeking Alpha
1 month ago
Acumen Pharmaceuticals, Inc. (ABOS) Q4 2024 Earnings Call Transcript
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS ) Q4 2024 Earnings Conference Call March 27, 2025 8:00 AM ET Company Participants Alex Braun - Head, Investor Relations Dan O'Connell - Chief Executive Officer Matt Zuga - Chief Financial Officer and Chief Business Officer Jim Doherty - President and Chief Development Officer Eric Siemers - Chief Medical Officer Conference Call Participants Jason Zemansky - Bank of America Pete Stavropoulos - Cantor Fitzgerald Ting Liu - UBS Tom Shrader - BTIG Ananda Ghosh - H. C. Wainwright & Company Operator Good day and welcome to Acumen Pharma Fiscal Year 2024 Conference Call and Webcast.
Acumen Pharmaceuticals, Inc. (ABOS) Q4 2024 Earnings Call Transcript
Neutral
GlobeNewsWire
2 months ago
Acumen Pharmaceuticals to Report Fourth Quarter and Year-End 2024 Financial Results on March 27, 2025
NEWTON, Mass., March 20, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer's disease, today announced that the Company will report fourth quarter and year-end 2024 financial results on Thursday, March 27, 2025. The Company will host a conference call and live audio webcast at 8:00 a.m. ET to provide a business and financial update.
Acumen Pharmaceuticals to Report Fourth Quarter and Year-End 2024 Financial Results on March 27, 2025
Neutral
GlobeNewsWire
2 months ago
Acumen Pharmaceuticals CEO Discusses Novel Targeted Therapies for Alzheimer's
NEW YORK, March 18, 2025 (GLOBE NEWSWIRE) -- Today's Marketplace (TMP) is proud to announce a featured interview with Acumen Pharmaceuticals (NASDAQ: ABOS) CEO Daniel O ' Connell and Jessica Clark, DNP, RN, Dean of the College of Nursing at Creighton University. The pair joined Today's Marketplace host Elizabeth Hart to discuss Alzheimer's Disease.
Acumen Pharmaceuticals CEO Discusses Novel Targeted Therapies for Alzheimer's
Neutral
GlobeNewsWire
2 months ago
Acumen Pharmaceuticals to Present During International Conference on Alzheimer's and Parkinson's Diseases 2025 and American Academy of Neurology Annual Meeting
Oral presentations will highlight the implementation of a validated research-use plasma pTau217 assay in the participant screening process for the Phase 2 ALTITUDE-AD study of sabirnetug Oral presentations will highlight the implementation of a validated research-use plasma pTau217 assay in the participant screening process for the Phase 2 ALTITUDE-AD study of sabirnetug
Acumen Pharmaceuticals to Present During International Conference on Alzheimer's and Parkinson's Diseases 2025 and American Academy of Neurology Annual Meeting
Neutral
GlobeNewsWire
2 months ago
Acumen Pharmaceuticals to Participate in Upcoming Investor Conferences
NEWTON, Mass., March 10, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer's disease, announced today that management will participate in webcast fireside chats at two upcoming investor conferences:
Acumen Pharmaceuticals to Participate in Upcoming Investor Conferences
Neutral
GlobeNewsWire
5 months ago
Acumen Pharmaceuticals to Participate in the 7th Annual Evercore ISI HealthCONx Conference
NEWTON, Mass., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer's disease, announced today that management will participate in a fireside chat at the 7th Annual Evercore ISI HealthCONx Conference on Tuesday, Dec. 3, 2024, at 3:00 p.m. ET.
Acumen Pharmaceuticals to Participate in the 7th Annual Evercore ISI HealthCONx Conference
Charts implemented using Lightweight Charts™